Plant-derived extracts in the neuroscience of anxietyon animal models: Biases and comments

International Journal of Neuroscience

Volumn 122, Issue 4, 2012, Pages 177-188

  Chirumbolo, Salvatore ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

anxiety; behavioral test; biases; GABA receptor; Gelsemium sempervirens; mice

Indexed keywords

21 HYDROXY 5ALPHA PREGN 16 ENE 3,20 DIONE; 3 OXOANDROSTA 16 ENE 17 CARBOXYLIC ACID; 3 OXOANDROSTA 4,16 DIENE 17 CARBOXYLIC ACID; ANXIOLYTIC AGENT; BUSPIRONE; CENTRAL DEPRESSANT AGENT; DIAZEPAM; GELSEDINE; GELSEMICINE; GELSEMIDINE; GELSEMINE; GELSEMIUM SEMPERVIRENS EXTRACT; GELSEVIRINE; KAVA EXTRACT; PASSIFLORA INCARNATA EXTRACT; PLANT EXTRACT; SCOPOLETIN; SCUTELLARIA BAICALENSIS EXTRACT; STEROID; TURNERA APHRODISIACA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIORAL SCIENCE; CENTRAL NERVOUS SYSTEM; DRUG ISOLATION; DRUG MECHANISM; HUMAN; LOCOMOTOR SYSTEM TUMOR; NONHUMAN; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GABA AGENTS; GELSEMIUM; HUMANS; MICE; OBSERVER VARIATION; PLANT EXTRACTS; RESEARCH;

EID: 84858269733     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.635829     Document Type: Article

References (103)

1. Lim L, Jin AZ, Ng TP. Anxiety and depression, chronic physical conditions, and quality of life in an urban population sample study. Soc Psychiatry Psychiatr Epidemiol. Forthcoming 2011 Aug 26, DOI: 10.1007/s00127-011-0420-6.
2. Mittal D, Fortney JC, Pyne JM, Edlund MJ,Wetherell JL. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr Serv. 2006 Dec;57(12):1731-7. (Pubitemid 46051327)
3. Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, Katon W, Sherbourne CD. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care. 2005 Dec;43(12):1164-70. (Pubitemid 43012172)
4. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000 May;157(5):669-82. (Pubitemid 30249642)
5. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, Kubzansky L, Lydiard RB, Massie MJ, Katon W, Laden SK, Stein MB. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry. 2008 May-Jun;30(3):208-25. (Pubitemid 351545834)
6. Cimpean D, Drake RE. Treating co-morbid chronic medical conditions and anxiety/depression. Epidemiol Psychiatr Sci. 2011 Jun;20(2):141-50.
7. Narayanan V, Heiming RS, Jansen F, Lesting J, Sachser N, Pape HC, Seidenbecher T. Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS One. 2011;6(7):e22600.
8. Tarantino LM, Sullivan PF, Meltzer-Brody S. Using animal models to disentangle the role of genetic, epigenetic, and environmental influences on behavioral outcomes associated with maternal anxiety and depression. Front Psychiatry. 2011;2:44.
9. Kokras N, Dalla C, Sideris A, Dendi A, Mikail HG, Antoniou K, Papadopoulou-Daifoti Z. Behavioral sexual dimorphism in models of anxiety and depression due to changes in HPA axis activity. Neuropharmacology. Forthcoming 2011, DOI:10.1016/J.neuropharm.2011.08.025.
10. Hettema JM, Webb BT, Guo AY, Zhao Z, Maher BS, Chen X, An SS, Sun C, Aggen SH, Kendler KS, Kuo PH, Otowa T, Flint J, van den Oord EJ. Prioritization and association analysis of murine-derived candidate genes in anxiety-spectrum disorders. Biol Psychiatry. Forthcoming 2011, DOI:10.1016/j.biopsych.2011.07. 012.
11. Graham BM, Milad MR. The study of fear extinction: implications for anxiety disorders. Am J Psychiatry. Forthcoming 2011 Aug 24, DOI: 10.1176/appi.ajp.2011.11040557.
12. Chang CH, Knapska E, Orsini CA, Rabinak CA, Zimmerman JM, Maren S. Fear extinction in rodents. Curr Protoc Neurosci. 2009 Apr;Chapter 8:Unit 8.23.
13. Magnani P, Conforti A, Zanolin E, Marzotto M, Bellavite P. Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice. Psychopharmacology (Berl). 2010 Jul;210(4):533-45.
14. Korte SM, De Boer SF. A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur J Pharmacol. 2003 Feb 28;463(1-3):163-75. (Pubitemid 36205078)
15. Korte SM, De Boer SF, Bohus B. Fear-potentiation in the elevated plus-maze test depends on stressor controllability and fear conditioning. Stress. 1999 Aug;3(1):27-40. (Pubitemid 29462672)
16. Grahn RE, Kalman BA, Brennan FX, Watkins LR, Maier SF. The elevated plus-maze is not sensitive to the effect of stressor controllability in rats. Pharmacol Biochem Behav. 1995 Nov;52(3):565-70.
17. Chirumbolo S. Gelsemine and Gelsemium sempervirens L. extracts in animal behavioral test: comments and related biases. Front Neurol. 2011;2:31.
18. Bellavite P. Gelsemium sempervirens and animal behavioral models. Front Neurol. 2011;2:56, DOI: 10.3389/fneur.2011.00056.
19. Ernst E. Herbal remedies for anxiety: a systematic review of controlled clinical trials. Phytomedicine. 2006 Feb;13(3):205-8. (Pubitemid 43120323)
20. Cassileth B. Kava (Piper methysticum). Oncology (Williston Park). 2011 Apr 15;25(4):384-5.
21. Sarris J, La Porte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiat. 2011 Jan;45(1):27-35.
22. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol. 2000 Feb;20(1):84-9. (Pubitemid 30056358)
23. Pittler MH, Edzard E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2001;4:CD003383.
24. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2002;2:CD003383.
25. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;1:CD003383.
26. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011 May;130(2):157-76.
27. Kumar S, Sharma A. Anti-anxiety activity studies of various extracts of Turnera aphrodisiaca Ward. J Herb Pharmacother. 2005;5(4):13-21.
28. Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia. 2001 Dec;72(8):922-6. (Pubitemid 33122201)
29. Demers, J. Gelsemium sempervirens. J Am Holistic Vet Med Assoc. 1998;16(4):21-22.
30. Dutt V, Dhar VJ, Sharma A. Antianxiety activity of Gelsemium sempervirens. Pharm Biol. 2010 Oct;48(10):1091-6.
31. Hui KM, Huen MS, Wang HY, Zheng H, Sigel E, Baur R, Ren H, Li ZW, Wong JT, Xue H. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002 Nov 1;64(9):1415-24. (Pubitemid 35248258)
32. Duke, JA. Handbook of phytochemical constituents of GRAS herbs and other economic plants. Boca Raton, FL: CRC Press; 1992.
33. Takayama H, Sakai SI. Gelsemium alkaloyds. In Cordell GA, editor. The alkaloyds: chemistry and pharmacology. Amsterdam: Elsevier; 1997. Vol. 49, p. 1-78.
34. Zhang Z, Wang P, Yuan W, Li S. Steroids, alkaloids, and coumarins from Gelsemium sempervirens. Planta Med. 2008 Dec;74(15):1818-22.
35. Nogure N, Nishiya C, Kitajima M, Takayama H. Six new alkaloids from Gelsemium sempervirens Ait. f. Thetrahedron Lett. 2005;46:5847-61.
36. Schun Y, Cordell GA. Cytotoxic steroids of Gelsemium sempervirens. J Nat Prod. 1987;50(2)195-8. (Pubitemid 17110602)
37. Williamson EM, Evans FJ. Potter's new encyclopaedia of botanical drugs and preparations. Rev. ed. Essex: SaffronWalden, the C. W. Daniel Co., Ltd.; 1988. 362 p. Reprint 1989.
38. Gahlot K, Abid M, Sharma A. Pharmacological evaluation of Gelsemium sempervirens roots for CNS depressant activity. Int J Pharmatech Res. 2011;3(2):693-7.
39. Bellavite P, Magnani P, Zanolin E, Conforti A. Homeopathic doses of Gelsemium sempervirens improve the behavior of mice in response to novel environments. Evid Based Complement Altern Med. 2011;2011:Art. ID 362517, 10 pp. DOI:10.1093/ecam/nep139.
40. Venard C, Boujedaini N, Mensah-Nyagan AG, Patte-Mensah C. Comparative analysis of gelsemine and Gelsemium sempervirens activity on neurosteroid allopregnanolone formation in the spinal cord and limbic system. Evid Based Complement Alternat Med. 2009 Jul 23;Art. ID 407617, DOI:10.1093/ecam/nep083.
41. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011, DOI:10.1016/j.euroneuro.2011. 04.002.
42. Williamson EH. Synergy and other interactions in phytomedicine. Phytomedicine. 2001;8(5):401-9.
43. Barreiro Arcos ML, Cremaschi G, Werner S, Coussio J, Ferraro G, Anesini C. Tilia cordata Mill. Extracts and scopoletin (isolated compound): differential cell growth effects on lymphocytes. Phytother Res. 2006 Jan;20(1):34-40. (Pubitemid 43171584)
44. Capra JC, Cunha MP, Machado DG, Zomkowski AD, Mendes BG, Santos AR, Pizzolatti MG, Rodrigues AL. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: evidence for the involvement of monoaminergic systems. Eur J Pharmacol. 2010 Sep 25;643(2-3):232-8.
45. Hornick A, Lieb A, Vo NP, Rollinger J, Stuppner H, Prast H. Effects of the coumarin scopoletin on learning and memory, on release of acetylcholine from brain synaptosomes and on long-term potentiation in hippocampus. BMC Pharmacol. 2008;8(Suppl 1):A36.
46. Rollinger JM, Hornick A, Langer T, Stuppner H, Prast H. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J Med Chem. 2004 Dec 2;47(25):6248-54. (Pubitemid 39587249)
47. Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine. 2007 Apr;14(4):289-300. (Pubitemid 46415622)
48. Venard C, Boujedaini N, Belon P, Mensah-Nyagan AG, Patte-Mensah C. Regulation of neurosteroid allopregnanolone biosynthesis in the rat spinal cord by glycine and the alkaloidal analogs strychnine and gelsemine. Neuroscience. 2008 Apr 22;153(1):154-61.
49. Chillingsworth FP. Physiological study of gelsemine and gelseminine. J Am Pharmac Assoc. 1914;3(3):315-21.
50. Yevenes GE, Zeilhofer HU. Allosteric modulation of glycine receptors. Br J Pharmacol. 2011 May 10, DOI: 10.1111/j.1476-5381.2011.01471.
51. WangDV,Wang F, Liu J, Zhang L,Wang Z, Lin L. Neurons in the amygdala with response-selectivity for anxiety in two ethologically based tests. PLoS One. 2011;6(4):e18739.
52. Zhang CG, Kim SJ. Taurine induces anti-anxiety by activating strychnine-sensitive glycine receptor in vivo. Annals Nutr Metab. 2007;51(4):379-86. (Pubitemid 47442981)
53. Riering K, Rewerts C, Zieglgansberger W. Analgesic effect of 5-HT3 receptor antagonists. Scand J Rheumatol. 2004;33(219):19-23. (Pubitemid 39180181)
54. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M. The sedative component of anesthesia is mediated by GABAA receptors in an endogenous sleep pathway. Nat Neurosci. 2002 Oct;5(10):979-84.
55. Forman SA, Miller KW. Anesthetic sites and allosteric mechanisms of action on cys-loop ligand-gated ion channels. Can J Anaesth. 2011;58:191-205.
56. Thompson AJ, Lester HA, Lummis SC. The structural basis of function in cys-loop receptors. Q Rev Biophys. 2010 Nov;43(4):449-99.
57. Olsen RW, Li GD. GABA-A receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15.
58. ChisariM, Eisenman LN, Covey DF, Mennerick S, Zorumski CF. The sticky issue of neurosteroids and GABA-A receptors. Trends Neurosci. 2010 Jul;33(7):299-306.
59. Hosie AM, Wilkins ME, Smart TG. Neurosteroid binding sites on GABA-A receptors. Pharmacol Ther. 2007 Oct;116(1):7-19. (Pubitemid 47398919)
60. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. Neurosteroid modulation of GABAA receptors. Prog Neurobiol. 2003 Sep;71(1):67-80.
61. Lambert JJ, Cooper MA, Simmons RD, Weir CJ, Belelli D. Neurosteroids: endogenous allosteric modulators of GABAA receptors. Psychoneuroendocrinology. 2009 Dec;34(Suppl 1):S48-58.
62. Rudolph U, Mohler H. GABA-based therapeutic approaches: GABA-A receptor subtype functions. Curr Opin Pharmacol. 2006;6:18-23. (Pubitemid 43103815)
63. Mitchell EA, HerdMB, Gunn BG, Lambert JJ, Belelli D. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem Int. 2008 Mar-Apr;52(4-5):588-95.
64. Tsetlin V, Kuzmin D, Kasheverov I. Assembly of nicotinic and other cys-loop receptors. J Neurochem. 2011 Mar;116(5):734-41.
65. Lader M. Effectiveness of benzodiazepines: do they work or not? Expert Rev Neurother. 2008 Aug;8(8):1189-91.
66. Martin JL, Sainz-Pardo M, Furukawa TA,Martín-Śanchez E, Seoane T, Gaĺan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007 Sep;21(7):774-82. (Pubitemid 47437920)
67. Atack JR. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci. 2010;2:331-60.
68. Auta J, Kadriu B, Giusti P, Costa E, Guidotti A. Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacol Biochem Behav. 2010 Jun;95(4):383-9.
69. Smoothy R, Berry MS. Alcohol increases both locomotion and immobility in mice: an ethological analysis of spontaneous motor activity. Psychopharmacology. 1984;83(3):272-6. (Pubitemid 14083651)
70. Araujo NP, Andersen ML, Abílio VC, Gomes DC, Carvalho RC, Silva RH, Ribeiro Rde A, Tufik S, Frussa-Filho R. Sleep deprivation abolishes the locomotor stimulant effect of ethanol in mice. Brain Res Bull. 2006 Apr 14;69(3):332-7.
71. Chuck TL, McLaughlin PJ, Arizzi-LaFrance MN, Salamone JD, Correa M. Comparison between multiple behavioral effects of peripheral ethanol administration in rats: sedation, ataxia, and bradykinesia. Life Sci. 2006 Jun 6;79(2): 154-61. (Pubitemid 43737067)
72. Biggio G, Concas A, Follesa P, Sanna E, Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol Ther. 2007 Oct;116(1):140-71. (Pubitemid 47391033)
73. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology. Forthcoming 2011 Aug 18, DOI:10.1016/j.neuropharm.2011.08. 018.
74. Kronfeld-Schor N, Einat H. Circadian rythms and depression: human psychopathology and animal models. Neuropharmacology. Forthcoming 2011, DOI: 10.1016/j.neuropharm.2011.08.020.
75. Bishop SJ. Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci. 2007 Jul;11(7):307-16. (Pubitemid 46962335)
76. Indovina I, Robbins TW, Ńũ nez-Elizalde AO, Dunn BD, Bishop SJ. Fear-conditioning mechanisms associated with trait vulnerability to anxiety in humans. Neuron. 2011 Feb 10;69(3):563-71.
77. Quartermain D, Clemente J, Shemer A. 5-HT1A agonists disrupt memory of fear conditioning in mice. Biol Psychiat. 1993 Feb 15;33(4):247-54. (Pubitemid 23091499)
78. Sanger DJ, Joly D. Anxiolytic drugs and the acquisition of fear conditioning in mice. Psychopharmacology (Berl). 1985;85(3):284-8. (Pubitemid 15123100)
79. Brignell CM, Curran HV. Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning. Psychopharmacology (Berl). 2006 Jul;186(4):504-16. (Pubitemid 43855837)
80. Bellavite P, Magnani P, Marzotto M, Conforti A. Assays of homeopathic remedies in rodent behavioral and psychopathological models. Homeopathy. 2009;98(4):208-27.
81. Tan KR, Rudolph U, L̈ uscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011 Apr;34(4):188-97.
82. Bond AJ, Wingrove J, Baylis M, Dalton J. Buspirone decreases physiological reactivity to unconditioned and conditioned aversive stimuli. Psychopharmacology (Berl). 2003 Jan;165(3):291-5. (Pubitemid 36197604)
83. Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev. 1985;9(1):37-44. (Pubitemid 15136669)
84. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463(1-3):3-33. (Pubitemid 36205070)
85. Jain A, Dvorkin A, Fonio E, Golani I, Gross CT. Validation of the dimensionality emergence assay for themeasurement of innate anxiety in laboratory mice. Eur Neuropsychopharmacol. Forthcoming 2011, DOI: 10.1016/j.euroneuro.2011.07.001.
86. Simon P, Dupuis R, Costentin J. Thigmotaxis as an index of anxiety in mice: influence of dopaminergic transmissions. Behav Brain Res. 1994 Mar 31;61(1):59-64. (Pubitemid 24097017)
87. Bourin M, Hascoet M. The mouse light/dark box test. Eur J Phrmacol. 2003;463(1-3):55-65. (Pubitemid 36205072)
88. Hascoet M, Bourin M. A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav. 1998;60(3):645-53. (Pubitemid 28341925)
89. Overstreet DH, Commissaris RC, De La Garza R II, File SE, Knapp DJ, Seiden LS. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress. 2003 Jun;6(2):101-10. (Pubitemid 36681960)
90. Karl T, Duffy L, Herzog H. Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci. 2008 Jul;28(1):173-80.
91. Calabrese EJ. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate. Crit Rev Toxicol. 2008;38(6):489-542. (Pubitemid 351962354)
92. Lewejohann L, Reinhard C, Schrewe A, Brandewiede J, Haemisch A, Gortz N, Schrachner M, Sachser N. Environmental bias? Effects of housing conditions, laboratory environment and experimenter on behavioral tests. Genes Brain Behav. 2006;5(1):64-72.
93. Vexler A, Tsai VM, Malinovsky Y. Estimation and testing based on data subject to measurement errors: from parametric to non-parametric likelihood methods. Stat Med. Forthcoming 2011, DOI: 10.1002/sim.4304.
94. McLeod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35(5):1203-8. (Pubitemid 38543544)
95. Jennions MD, Møller AP. A survey on the statistical power of research in behavioral ecology and animal behavior. Behav Ecol. 2003;14:438-45. (Pubitemid 36647008)
96. Nakagawa S. A farewell to Bonferroni: the problems of low statistical power and publication bias. Behav Ecol. 2004;15(6):1044-5. (Pubitemid 39471217)
97. Hoenig JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat. 2001;55:19-24.
98. Adebiyl AO. Bias: a review of current understanding. Afr J Med Med Sci. 2010;39(3):241-8.
99. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):1-220.
100. Longordo F, Fan J, Steimer T, Kopp C, Luthl A. Do mice habituate to "gentle handling"? A comparison of resting behavior, corticosterone levels and synaptic function in handled and undisturbed C57BL/6J mice. Sleep. 2011;34(5):679-81.
101. Podsakoff PM, MacKenzie SB, Lee JY, Podsakoff NP. Common method biases in behavioral research: a critical review of he literature and recommended remedies. J Appl Psychol. 2003;88(5):879-903. (Pubitemid 37239703)
102. Ackermann TF, Ḧortnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F, Hellweg R, Lang UE. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem. 2008;22(5-6):735-44.
103. Tohda C, Nakanishi R, Kadowaki M. Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev 2009 Jan;31(1):69-74.